TY - JOUR AU - Hatooka, Masahiro AU - Kawaoka, Tomokazu AU - Aikata, Hiroshi AU - Inagaki, Yuki AU - Morio, Kei AU - Nakahara, Takashi AU - Murakami, Eisuke AU - Tsuge, Masataka AU - Hiramatsu, Akira AU - Imamura, Michio AU - Kawakami, Yoshiiku AU - Awai, Kazuo AU - Masaki, Keiichi AU - Waki, Koji AU - Kohno, Hirotaka AU - Kohno, Hiroshi AU - Moriya, Takashi AU - Nagaoki, Yuko AU - Tamura, Toru AU - Amano, Hajime AU - Katamura, Yoshio AU - Chayama, Kazuaki PY - 2018 DA - 2018/06/04 TI - Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial JO - BMC Cancer SP - 633 VL - 18 IS - 1 AB - In patients with advanced hepatocellular carcinoma (HCC), evidence is unclear as to whether hepatic arterial infusion chemotherapy (HAIC) or sorafenib is superior. We performed a prospective, open-label, non-comparative phase II study to assess survival with HAIC or HAIC converted to sorafenib. SN - 1471-2407 UR - https://doi.org/10.1186/s12885-018-4519-y DO - 10.1186/s12885-018-4519-y ID - Hatooka2018 ER -